Metacrine Key Executives
This section highlights Metacrine's key executives, including their titles and compensation details.
Find Contacts at Metacrine
(Showing 0 of )
Metacrine Earnings
This section highlights Metacrine's earnings, including key dates, EPS, earnings reports, and earnings call transcripts.
Next Earnings Date
Last Earnings Results
Earnings Call Transcripts
| Transcript | Quarter | Year | Date | Estimated EPS | Actual EPS |
|---|
Metacrine, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing therapies for patients with gastrointestinal diseases. It is developing MET642, which has completed Phase I clinical trial for the treatment of ulcerative colitis. Metacrine, Inc. was incorporated in 2014 and is headquartered in San Diego, California.
$0.58
Stock Price
$-
Market Cap
32
Employees
San Diego, CA
Location
Financial Statements
Access annual & quarterly financial statements for Metacrine, including income statements, balance sheets, and cash flow statements..
Annual Income Statement
| Breakdown | December 31, 2021 | December 31, 2020 | December 31, 2019 | December 31, 2018 |
|---|---|---|---|---|
| Revenue | $- | $- | $- | $1.45M |
| Cost of Revenue | $- | $- | $- | $- |
| Gross Profit | $- | $- | $- | $1.45M |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 100.00% |
| Research and Development Expenses | $45.47M | $26.79M | $25.97M | $22.94M |
| General and Administrative Expenses | $15.61M | $9.90M | $4.03M | $5.24M |
| Selling and Marketing Expenses | $- | $- | $- | $- |
| Selling General and Administrative Expenses | $15.61M | $9.90M | $4.03M | $5.24M |
| Other Expenses | $- | $-614.00K | $- | $- |
| Operating Expenses | $61.08M | $36.69M | $30.00M | $28.18M |
| Cost and Expenses | $61.08M | $36.69M | $30.00M | $28.18M |
| Interest Income | $102.00K | $494.00K | $1.42M | $934.00K |
| Interest Expense | $1.20M | $1.01M | $347.00K | $- |
| Depreciation and Amortization | $972.00K | $931.00K | $2.25M | $829.00K |
| EBITDA | $-61.08M | $-36.69M | $-27.76M | $-24.99M |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | -1723.59% |
| Operating Income | $-61.08M | $-36.69M | $-30.00M | $-26.73M |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | -1843.38% |
| Total Other Income Expenses Net | $-1.13M | $-614.00K | $1.07M | $908.00K |
| Income Before Tax | $-62.21M | $-37.30M | $-28.93M | $-25.82M |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | -1780.76% |
| Income Tax Expense | $-972.00K | $-931.00K | $347.00K | $908.00K |
| Net Income | $-61.23M | $-36.37M | $-29.28M | $-25.82M |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | -1780.76% |
| EPS | $-1.45 | $-3.87 | $-1.52 | $-1.35 |
| EPS Diluted | $-1.45 | $-3.87 | $-1.52 | $-1.35 |
| Weighted Average Shares Outstanding | 42.11M | 9.40M | 19.22M | 19.06M |
| Weighted Average Shares Outstanding Diluted | 42.11M | 9.40M | 19.22M | 19.06M |
| SEC Filing | Source | Source | Source | Source |
| Breakdown | September 30, 2022 | June 30, 2022 | March 31, 2022 | December 31, 2021 | September 30, 2021 | June 30, 2021 | March 31, 2021 | December 31, 2020 | September 30, 2020 | June 30, 2020 | March 31, 2020 | December 31, 2019 | September 30, 2019 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Cost of Revenue | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Gross Profit | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research and Development Expenses | $1.32M | $2.31M | $6.68M | $9.18M | $14.07M | $11.37M | $10.86M | $6.82M | $6.22M | $7.39M | $6.36M | $6.48M | $7.65M |
| General and Administrative Expenses | $3.84M | $3.41M | $5.48M | $3.91M | $4.01M | $3.99M | $3.70M | $3.81M | $2.69M | $1.79M | $1.60M | $974.00K | $1.07M |
| Selling and Marketing Expenses | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Selling General and Administrative Expenses | $3.84M | $3.41M | $5.48M | $3.91M | $4.01M | $3.99M | $3.70M | $3.81M | $2.69M | $1.79M | $1.60M | $974.00K | $1.07M |
| Other Expenses | $-35.00K | $-53.00K | $23.00K | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Operating Expenses | $5.16M | $5.72M | $12.16M | $13.09M | $18.08M | $15.36M | $14.55M | $10.63M | $8.91M | $9.19M | $7.96M | $7.45M | $8.72M |
| Cost and Expenses | $5.16M | $5.72M | $12.16M | $13.09M | $18.08M | $15.36M | $14.55M | $10.63M | $8.91M | $9.19M | $7.96M | $7.45M | $8.72M |
| Interest Income | $228.00K | $67.00K | $23.00K | $17.00K | $22.00K | $27.00K | $36.00K | $49.00K | $82.00K | $134.00K | $229.00K | $307.00K | $344.00K |
| Interest Expense | $550.00K | $511.00K | $414.00K | $459.00K | $252.00K | $247.00K | $244.00K | $247.00K | $258.00K | $254.00K | $253.00K | $254.00K | $93.00K |
| Depreciation and Amortization | $193.00K | $58.00K | $643.00K | $-434.00K | $244.00K | $242.00K | $243.00K | $251.00K | $234.00K | $226.00K | $220.00K | $211.00K | $209.00K |
| EBITDA | $-4.97M | $-5.71M | $-11.87M | $-13.50M | $-17.83M | $-15.10M | $-14.28M | $-10.32M | $-8.56M | $-8.84M | $-7.64M | $-6.93M | $-8.16M |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | $-5.16M | $-5.76M | $-12.51M | $-13.07M | $-18.08M | $-15.36M | $-14.55M | $-10.63M | $-8.91M | $-9.19M | $-7.96M | $-7.45M | $-8.72M |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income Expenses Net | $-357.00K | $-497.00K | $-368.00K | $-439.00K | $-249.00K | $-225.00K | $-215.00K | $-186.00K | $-144.00K | $-134.00K | $-150.00K | $53.00K | $251.00K |
| Income Before Tax | $-5.52M | $-6.26M | $-12.88M | $-13.53M | $-18.33M | $-15.59M | $-14.77M | $-10.82M | $-9.05M | $-9.32M | $-8.11M | $-7.40M | $-8.46M |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | $-193.00K | $497.00K | $368.00K | $459.00K | $3.00K | $22.00K | $29.00K | $61.00K | $114.00K | $120.00K | $103.00K | $307.00K | $344.00K |
| Net Income | $-5.33M | $-6.76M | $-13.25M | $-13.98M | $-18.33M | $-15.59M | $-14.77M | $-10.82M | $-9.05M | $-9.32M | $-8.11M | $-7.40M | $-8.46M |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | $-0.13 | $-0.16 | $-0.31 | $-0.33 | $-0.69 | $-0.59 | $-0.56 | $-0.42 | $-7.17 | $-0.36 | $-0.42 | $-0.38 | $-0.44 |
| EPS Diluted | $-0.13 | $-0.16 | $-0.31 | $-0.33 | $-0.69 | $-0.59 | $-0.56 | $-0.42 | $-7.17 | $-0.36 | $-0.42 | $-0.38 | $-0.44 |
| Weighted Average Shares Outstanding | 42.57M | 42.43M | 42.13M | 42.11M | 26.52M | 26.37M | 26.21M | 25.97M | 1.26M | 25.92M | 19.22M | 19.22M | 19.22M |
| Weighted Average Shares Outstanding Diluted | 42.57M | 42.43M | 42.13M | 42.11M | 26.52M | 26.37M | 26.21M | 25.97M | 1.26M | 25.92M | 19.22M | 19.22M | 19.22M |
| SEC Filing | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source |
Annual Balance Sheet
| Breakdown | December 31, 2021 | December 31, 2020 | December 31, 2019 | December 31, 2018 |
|---|---|---|---|---|
| Cash and Cash Equivalents | $76.43M | $96.18M | $15.67M | $15.96M |
| Short Term Investments | $27.52M | $71.78M | $39.98M | $57.02M |
| Cash and Short Term Investments | $76.43M | $96.18M | $55.65M | $72.99M |
| Net Receivables | $26.00K | $- | $- | $- |
| Inventory | $1.82M | $- | $- | $- |
| Other Current Assets | $468.00K | $5.85M | $- | $1.13M |
| Total Current Assets | $78.74M | $102.02M | $57.34M | $74.12M |
| Property Plant Equipment Net | $1.25M | $2.21M | $2.94M | $3.68M |
| Goodwill | $- | $- | $- | $- |
| Intangible Assets | $- | $- | $- | $- |
| Goodwill and Intangible Assets | $- | $- | $- | $- |
| Long Term Investments | $- | $- | $- | $- |
| Tax Assets | $- | $- | $- | $- |
| Other Non-Current Assets | $- | $- | $- | $- |
| Total Non-Current Assets | $1.25M | $2.21M | $2.94M | $3.68M |
| Other Assets | $- | $- | $- | $- |
| Total Assets | $79.99M | $104.24M | $60.28M | $77.80M |
| Account Payables | $368.00K | $334.00K | $239.00K | $1.20M |
| Short Term Debt | $825.00K | $741.00K | $9.70M | $- |
| Tax Payables | $- | $- | $- | $- |
| Deferred Revenue | $- | $- | $3.55M | $- |
| Other Current Liabilities | $6.57M | $2.95M | $525.00K | $3.05M |
| Total Current Liabilities | $7.76M | $4.03M | $14.01M | $4.25M |
| Long Term Debt | $13.30M | $9.37M | $1.75M | $- |
| Deferred Revenue Non-Current | $- | $- | $- | $- |
| Deferred Tax Liabilities Non-Current | $- | $- | $- | $- |
| Other Non-Current Liabilities | $1.57M | $1.56M | $122.76M | $125.02M |
| Total Non-Current Liabilities | $14.87M | $10.93M | $124.51M | $125.02M |
| Other Liabilities | $- | $- | $- | $- |
| Total Liabilities | $22.63M | $14.96M | $138.52M | $129.27M |
| Preferred Stock | $- | $104.24M | $- | $- |
| Common Stock | $4.00K | $3.00K | $- | $- |
| Retained Earnings | $-182.95M | $-120.75M | $-83.44M | $-54.51M |
| Accumulated Other Comprehensive Income Loss | $-5.00K | $1.00K | $41.00K | $-475.00K |
| Other Total Stockholders Equity | $240.31M | $105.78M | $5.16M | $3.52M |
| Total Stockholders Equity | $57.35M | $89.28M | $-78.24M | $-51.47M |
| Total Equity | $57.35M | $89.28M | $-78.24M | $-51.47M |
| Total Liabilities and Stockholders Equity | $79.99M | $104.24M | $60.28M | $77.80M |
| Minority Interest | $- | $- | $- | $- |
| Total Liabilities and Total Equity | $79.99M | $104.24M | $60.28M | $77.80M |
| Total Investments | $27.52M | $71.78M | $39.98M | $57.02M |
| Total Debt | $14.13M | $9.37M | $11.45M | $2.85M |
| Net Debt | $-62.30M | $-86.80M | $-4.22M | $-13.11M |
Balance Sheet Charts
| Breakdown | September 30, 2022 | June 30, 2022 | March 31, 2022 | December 31, 2021 | September 30, 2021 | June 30, 2021 | March 31, 2021 | December 31, 2020 | September 30, 2020 | June 30, 2020 | December 31, 2019 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash and Cash Equivalents | $52.75M | $45.35M | $33.03M | $48.91M | $17.03M | $17.15M | $19.46M | $24.39M | $98.28M | $17.13M | $15.67M |
| Short Term Investments | $- | $10.18M | $29.65M | $27.52M | $44.70M | $57.67M | $65.00M | $71.78M | $10.96M | $22.16M | $39.98M |
| Cash and Short Term Investments | $52.75M | $55.53M | $62.69M | $76.43M | $61.73M | $74.81M | $84.46M | $96.18M | $109.24M | $39.28M | $55.65M |
| Net Receivables | $55.00K | $35.00K | $709.00K | $- | $67.00K | $81.00K | $193.00K | $- | $- | $- | $- |
| Inventory | $- | $-35.00K | $3.14M | $- | $- | $- | $- | $- | $- | $- | $- |
| Other Current Assets | $2.23M | $3.61M | $196.00K | $2.31M | $3.79M | $4.76M | $6.06M | $5.85M | $1.66M | $2.09M | $1.69M |
| Total Current Assets | $55.04M | $59.14M | $66.74M | $78.74M | $65.58M | $79.65M | $90.71M | $102.02M | $110.90M | $41.38M | $57.34M |
| Property Plant Equipment Net | $- | $- | $- | $1.25M | $1.49M | $1.74M | $1.97M | $2.21M | $2.43M | $2.66M | $2.94M |
| Goodwill | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Intangible Assets | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Goodwill and Intangible Assets | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Long Term Investments | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Tax Assets | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Other Non-Current Assets | $- | $- | $- | $- | $438.00K | $- | $- | $- | $- | $571.00K | $- |
| Total Non-Current Assets | $- | $- | $- | $1.25M | $1.93M | $1.74M | $1.97M | $2.21M | $2.43M | $3.23M | $2.94M |
| Other Assets | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Total Assets | $55.04M | $59.14M | $66.74M | $79.99M | $67.51M | $81.39M | $92.68M | $104.24M | $113.33M | $44.60M | $60.28M |
| Account Payables | $691.00K | $503.00K | $264.00K | $368.00K | $323.00K | $261.00K | $325.00K | $334.00K | $655.00K | $233.00K | $239.00K |
| Short Term Debt | $1.21M | $- | $- | $825.00K | $1.26M | $782.00K | $762.00K | $9.24M | $722.00K | $9.24M | $9.10M |
| Tax Payables | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Deferred Revenue | $- | $- | $- | $- | $- | $- | $- | $- | $-722.00K | $- | $- |
| Other Current Liabilities | $2.63M | $2.15M | $5.21M | $6.57M | $8.77M | $6.45M | $4.15M | $-5.55M | $3.45M | $5.13M | $4.67M |
| Total Current Liabilities | $4.53M | $2.65M | $5.47M | $7.76M | $10.36M | $7.49M | $5.24M | $4.03M | $4.10M | $14.60M | $14.01M |
| Long Term Debt | $12.58M | $13.62M | $13.43M | $13.48M | $9.50M | $10.10M | $10.24M | $9.37M | $9.31M | $- | $- |
| Deferred Revenue Non-Current | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Deferred Tax Liabilities Non-Current | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Other Non-Current Liabilities | $863.00K | $1.39M | $1.39M | $1.39M | $531.00K | $536.00K | $544.00K | $1.56M | $1.76M | $1.45M | $124.51M |
| Total Non-Current Liabilities | $13.44M | $15.00M | $14.81M | $14.87M | $10.03M | $10.64M | $10.79M | $10.93M | $11.07M | $1.45M | $124.51M |
| Other Liabilities | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Total Liabilities | $17.97M | $17.66M | $20.29M | $22.63M | $20.39M | $18.13M | $16.02M | $14.96M | $15.17M | $16.05M | $138.52M |
| Preferred Stock | $- | $- | $- | $- | $- | $- | $- | $- | $113.33M | $- | $- |
| Common Stock | $4.00K | $4.00K | $4.00K | $4.00K | $3.00K | $3.00K | $3.00K | $3.00K | $3.00K | $2.00K | $- |
| Retained Earnings | $-207.62M | $-202.09M | $-195.83M | $-182.95M | $-169.43M | $-151.10M | $-135.51M | $-120.75M | $-109.93M | $-100.88M | $-83.44M |
| Accumulated Other Comprehensive Income Loss | $- | $-20.00K | $-43.00K | $-5.00K | $2.00K | $7.00K | $-1.00K | $1.00K | $-919.00K | $-842.00K | $-702.00K |
| Other Total Stockholders Equity | $244.68M | $243.59M | $242.32M | $240.31M | $216.54M | $214.35M | $212.17M | $210.02M | $95.68M | $130.27M | $5.91M |
| Total Stockholders Equity | $37.06M | $41.48M | $46.45M | $57.35M | $47.12M | $63.26M | $76.66M | $89.28M | $98.16M | $28.56M | $-78.24M |
| Total Equity | $37.06M | $41.48M | $46.45M | $57.35M | $47.12M | $- | $- | $- | $- | $- | $- |
| Total Liabilities and Stockholders Equity | $55.04M | $59.14M | $66.74M | $79.99M | $67.51M | $81.39M | $92.68M | $104.24M | $113.33M | $44.60M | $60.28M |
| Minority Interest | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Total Liabilities and Total Equity | $55.04M | $59.14M | $66.74M | $79.99M | $67.51M | $81.39M | $92.68M | $104.24M | $113.33M | $44.60M | $60.28M |
| Total Investments | $- | $10.18M | $29.65M | $27.52M | $44.70M | $57.67M | $65.00M | $71.78M | $10.96M | $22.16M | $39.98M |
| Total Debt | $13.79M | $13.62M | $13.43M | $14.31M | $10.76M | $10.88M | $11.01M | $18.61M | $11.23M | $11.31M | $11.45M |
| Net Debt | $-38.96M | $-31.73M | $-19.61M | $-34.60M | $-6.26M | $-6.26M | $-8.45M | $-5.78M | $-87.05M | $-5.82M | $-4.22M |
Annual Cash Flow
| Breakdown | December 31, 2021 | December 31, 2020 | December 31, 2019 | December 31, 2018 |
|---|---|---|---|---|
| Net Income | $-62.21M | $-37.30M | $-28.93M | $-25.82M |
| Depreciation and Amortization | $972.00K | $931.00K | $830.00K | $829.00K |
| Deferred Income Tax | $342.00K | $126.00K | $-649.00K | $- |
| Stock Based Compensation | $6.95M | $5.02M | $1.93M | $1.06M |
| Change in Working Capital | $6.44M | $-5.26M | $-1.02M | $-1.03M |
| Accounts Receivables | $- | $- | $- | $- |
| Inventory | $- | $- | $- | $- |
| Accounts Payables | $3.65M | $-503.00K | $- | $- |
| Other Working Capital | $2.79M | $-4.75M | $- | $-1.03M |
| Other Non Cash Items | $342.00K | $273.00K | $91.00K | $-517.00K |
| Net Cash Provided by Operating Activities | $-47.16M | $-36.21M | $-27.75M | $-25.48M |
| Investments in Property Plant and Equipment | $-8.00K | $-206.00K | $-84.00K | $-690.00K |
| Acquisitions Net | $- | $- | $- | $- |
| Purchases of Investments | $-42.67M | $-79.87M | $-53.03M | $-73.04M |
| Sales Maturities of Investments | $86.59M | $47.98M | $70.81M | $16.50M |
| Other Investing Activities | $- | $- | $- | $15.00K |
| Net Cash Used for Investing Activities | $43.91M | $-32.10M | $17.70M | $-57.22M |
| Debt Repayment | $- | $- | $- | $- |
| Common Stock Issued | $21.66M | $76.87M | $- | $- |
| Common Stock Repurchased | $-1.00K | $-2.00K | $-1.00K | $-3.00K |
| Dividends Paid | $- | $- | $- | $- |
| Other Financing Activities | $27.77M | $77.03M | $9.75M | $64.81M |
| Net Cash Used Provided by Financing Activities | $27.77M | $77.03M | $9.75M | $64.81M |
| Effect of Forex Changes on Cash | $- | $- | $- | $- |
| Net Change in Cash | $24.52M | $8.72M | $-297.00K | $-17.89M |
| Cash at End of Period | $48.91M | $24.39M | $15.67M | $15.96M |
| Cash at Beginning of Period | $24.39M | $15.67M | $15.96M | $33.86M |
| Operating Cash Flow | $-47.16M | $-36.21M | $-27.75M | $-25.48M |
| Capital Expenditure | $-8.00K | $-206.00K | $-84.00K | $-690.00K |
| Free Cash Flow | $-47.17M | $-36.42M | $-27.83M | $-26.17M |
Cash Flow Charts
| Breakdown | September 30, 2022 | June 30, 2022 | March 31, 2022 | December 31, 2021 | September 30, 2021 | June 30, 2021 | March 31, 2021 | December 31, 2020 | September 30, 2020 | June 30, 2020 | March 31, 2020 | December 31, 2019 | September 30, 2019 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Income | $-5.52M | $-6.26M | $-12.88M | $-13.53M | $-18.33M | $-15.59M | $-14.77M | $-10.82M | $-9.05M | $-9.32M | $-8.11M | $-7.40M | $-8.46M |
| Depreciation and Amortization | $- | $64.00K | $247.00K | $-434.00K | $244.00K | $242.00K | $243.00K | $251.00K | $234.00K | $226.00K | $220.00K | $211.00K | $209.00K |
| Deferred Income Tax | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Stock Based Compensation | $1.08M | $1.27M | $2.01M | $1.69M | $2.15M | $1.59M | $1.52M | $1.87M | $1.79M | $857.00K | $503.00K | $490.00K | $484.00K |
| Change in Working Capital | $1.47M | $-3.08M | $-2.69M | $-411.00K | $2.78M | $3.47M | $603.00K | $-3.60M | $-1.05M | $721.00K | $-1.33M | $-2.38M | $1.81M |
| Accounts Receivables | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Inventory | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Accounts Payables | $- | $- | $-1.46M | $3.65M | $- | $- | $1.19M | $-503.00K | $- | $- | $- | $- | $- |
| Other Working Capital | $- | $- | $-1.23M | $-4.06M | $2.78M | $3.47M | $-586.00K | $-3.10M | $-1.05M | $721.00K | $-1.33M | $-2.38M | $1.81M |
| Other Non Cash Items | $174.00K | $122.00K | $-385.00K | $848.00K | $124.00K | $157.00K | $232.00K | $205.00K | $13.00K | $64.00K | $117.00K | $-2.00K | $-101.00K |
| Net Cash Provided by Operating Activities | $-2.80M | $-7.89M | $-13.70M | $-11.83M | $-13.02M | $-10.13M | $-12.17M | $-12.09M | $-8.06M | $-7.45M | $-8.60M | $-9.08M | $-6.06M |
| Investments in Property Plant and Equipment | $- | $- | $- | $-8.00K | $- | $-8.00K | $- | $-34.00K | $-7.00K | $-92.00K | $-73.00K | $-28.00K | $-5.00K |
| Acquisitions Net | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Purchases of Investments | $- | $-12.68M | $-12.68M | $-3.50M | $-4.50M | $-21.90M | $-12.78M | $-71.93M | $- | $- | $-7.94M | $-4.20M | $-17.73M |
| Sales Maturities of Investments | $10.20M | $19.50M | $10.50M | $20.65M | $17.40M | $29.15M | $19.39M | $10.95M | $11.14M | $12.20M | $13.69M | $10.59M | $20.25M |
| Other Investing Activities | $- | $13.38M | $- | $8.00K | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Net Cash Used for Investing Activities | $10.20M | $20.20M | $-2.18M | $17.15M | $12.90M | $7.24M | $6.61M | $-61.01M | $11.14M | $12.11M | $5.67M | $6.36M | $2.52M |
| Debt Repayment | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Common Stock Issued | $- | $- | $- | $21.66M | $- | $- | $- | $-876.00K | $- | $- | $- | $- | $- |
| Common Stock Repurchased | $- | $- | $- | $185.00K | $- | $-1.00K | $- | $-2.00K | $- | $- | $-2.00K | $- | $- |
| Dividends Paid | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Other Financing Activities | $- | $1.00K | $- | $26.56M | $- | $582.00K | $623.00K | $-784.00K | $78.08M | $-254.00K | $-9.00K | $8.00K | $9.72M |
| Net Cash Used Provided by Financing Activities | $- | $1.00K | $- | $26.56M | $- | $582.00K | $623.00K | $-784.00K | $78.08M | $-254.00K | $-9.00K | $8.00K | $9.72M |
| Effect of Forex Changes on Cash | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Net Change in Cash | $7.40M | $12.31M | $-15.88M | $31.88M | $-118.00K | $-2.31M | $-4.94M | $-73.89M | $81.15M | $4.40M | $-2.94M | $-2.71M | $6.17M |
| Cash at End of Period | $52.75M | $45.35M | $33.03M | $48.91M | $17.03M | $17.15M | $19.46M | $24.39M | $98.28M | $17.13M | $12.73M | $15.67M | $18.38M |
| Cash at Beginning of Period | $45.35M | $33.03M | $48.91M | $17.03M | $17.15M | $19.46M | $24.39M | $98.28M | $17.13M | $12.73M | $15.67M | $18.38M | $12.21M |
| Operating Cash Flow | $-2.80M | $-7.89M | $-13.70M | $-11.83M | $-13.02M | $-10.13M | $-12.17M | $-12.09M | $-8.06M | $-7.45M | $-8.60M | $-9.08M | $-6.06M |
| Capital Expenditure | $- | $- | $- | $-8.00K | $- | $-8.00K | $- | $-34.00K | $-7.00K | $-92.00K | $-73.00K | $-28.00K | $-5.00K |
| Free Cash Flow | $-2.80M | $-7.89M | $-13.70M | $-11.84M | $-13.02M | $-10.14M | $-12.17M | $-12.12M | $-8.07M | $-7.55M | $-8.68M | $-9.11M | $-6.07M |
Metacrine Dividends
Explore Metacrine's dividend history, including dividend yield, payout ratio, and historical payments.
Dividend Yield
-
Dividend Payout Ratio
-
Dividend Paid & Capex Coverage Ratio
-5895.00x
Metacrine Dividend History
| Dividend | Adjusted Dividend | Date | Record Date | Payment Date | Declaration Date |
|---|---|---|---|---|---|
| $0.58 | $0.58 | June 21, 2023 |
Metacrine News
Read the latest news about Metacrine, including recent articles, headlines, and updates.
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates LOTZ, ECOM, MTCR, MNRL
NEW YORK , Oct. 6, 2022 /PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: CarLotz, Inc. (NASDAQ: LOTZ)'s sale to Shift Technologies, Inc. for 0.692158 shares of Shift common stock for each share of CarLotz common stock. If you are a CarLotz shareholder, click here to learn more about your rights and options.
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates EQ, MTCR, STOR, RCKT
NEW YORK , Sept. 26, 2022 /PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: Equillium, Inc. (NASDAQ: EQ) 's merger with Metacrine Inc. If you are an Equillium shareholder, click here to learn more about your rights and options.
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates ECOM, SGFY, EQ, MTCR
NEW YORK , Sept. 19, 2022 /PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: ChannelAdvisor Corporation (NYSE: ECOM) 's sale to CommerceHub for $23.10 per share in cash.
Metacrine Achieves Full Enrollment for MET642 Phase 2a Trial in Patients With Nash
SAN DIEGO, Sept. 09, 2021 (GLOBE NEWSWIRE) -- Metacrine, Inc. (NASDAQ:MTCR), a clinical-stage biopharmaceutical company pioneering differentiated therapies for patients with liver and gastrointestinal diseases, today announced that it has completed enrollment for its Phase 2a trial evaluating MET642, an optimized farnesoid X receptor (FXR) agonist, in patients with non-alcoholic steatohepatitis (NASH). The Company plans to report interim data from the first 60 patients early in the fourth quarter of 2021.
Metacrine to Host Virtual R&D Day for Analysts and Investors on September 15, 2021
SAN DIEGO, Sept. 08, 2021 (GLOBE NEWSWIRE) -- Metacrine, Inc. (NASDAQ:MTCR), a clinical-stage biopharmaceutical company pioneering differentiated therapies for patients with liver and gastrointestinal diseases, today announced it will host a virtual R&D Day for analysts and investors on Wednesday, September 15, 2021 at 12:00 p.m. ET. The event will showcase Metacrine's programs in non-alcoholic steatohepatitis (NASH) and inflammatory bowel disease (IBD), as well as the introduction of a new discovery program.
Metacrine to Present at H.C. Wainwright 23rd Annual Global Investment Conference
SAN DIEGO, Sept. 07, 2021 (GLOBE NEWSWIRE) -- Metacrine, Inc. (NASDAQ:MTCR), a clinical-stage biopharmaceutical company pioneering differentiated therapies for patients with liver and gastrointestinal diseases, today announced that Preston Klassen, M.D., MHS, president and chief executive officer, will present virtually at the H.C. Wainwright 23rd Annual Global Investment Conference at 7:00 a.m. ET on Monday, September 13, 2021.
Metacrine Updates MET642 Clinical Development Milestone and Reports Second-Quarter 2021 Results
SAN DIEGO, Aug. 12, 2021 (GLOBE NEWSWIRE) -- Metacrine, Inc. (NASDAQ:MTCR), a clinical-stage biopharmaceutical company pioneering differentiated therapies for patients with liver and gastrointestinal diseases, today updated a key clinical development milestone and reported its second-quarter 2021 financial results.
Metacrine to Present at 2021 Canaccord Genuity Growth Conference
SAN DIEGO, Aug. 09, 2021 (GLOBE NEWSWIRE) -- Metacrine, Inc. (NASDAQ:MTCR), a clinical-stage biopharmaceutical company pioneering differentiated therapies for patients with liver and gastrointestinal diseases, today announced that Preston Klassen, M.D., MHS, president and chief executive officer, will present virtually at the 2021 Canaccord Genuity Growth Conference at 12:30 p.m. ET on Thursday, August 12, 2021.
Metacrine to Present New Preclinical Data in Inflammatory Bowel Disease (IBD) at European Crohn's and Colitis Organisation (ECCO) 2021 Virtual Congress
SAN DIEGO, July 06, 2021 (GLOBE NEWSWIRE) -- Metacrine, Inc. (NASDAQ:MTCR), a clinical-stage biopharmaceutical company pioneering differentiated therapies for patients with liver and gastrointestinal diseases, today announced that it will present new preclinical data at the European Crohn's and Colitis Organisation (ECCO) 2021 Virtual Congress on July 9, 2021.
Metacrine and Its Partners to Present Data at the EASL International Liver Congress™ 2021
SAN DIEGO, June 17, 2021 (GLOBE NEWSWIRE) -- Metacrine, Inc. (NASDAQ:MTCR), a clinical-stage biopharmaceutical company pioneering differentiated therapies for patients with liver and gastrointestinal diseases, today announced that it will present data at the European Association for the Study of the Liver (EASL) International Liver Congress™ 2021, being held virtually from June 23-26, 2021. Data to be presented includes results from the Company's Phase 1 trial of MET642, a farnesoid X receptor (FXR) agonist being developed for the treatment of non-alcoholic steatohepatitis (NASH), as well as one oral presentation and one poster focused on preclinical studies examining FXR agonists in rare adult and pediatric cholestatic liver diseases.
Metacrine Achieves Full Enrollment for MET409 Phase 2a Combination Trial in Patients With Type 2 Diabetes and NASH
SAN DIEGO, June 02, 2021 (GLOBE NEWSWIRE) -- Metacrine, Inc. (NASDAQ:MTCR), a clinical-stage biopharmaceutical company pioneering differentiated therapies for patients with liver and gastrointestinal diseases, today announced that it has completed enrollment for its Phase 2a trial evaluating MET409 in combination with empagliflozin (Jardiance®), a sodium-glucose cotransport-2 (SGLT2) inhibitor, in patients with type 2 diabetes and non-alcoholic steatohepatitis (NASH). The Company plans to report topline data in the fourth quarter of 2021.
Metacrine to Present at 2021 Jefferies Healthcare Conference
SAN DIEGO, May 26, 2021 (GLOBE NEWSWIRE) -- Metacrine, Inc. (NASDAQ:MTCR), a clinical-stage biopharmaceutical company pioneering differentiated therapies for patients with liver and gastrointestinal diseases, today announced that Preston Klassen, M.D., MHS, president and chief executive officer, will present virtually at the 2021 Jefferies Healthcare Conference at 11:00 a.m. ET on Friday, June 4, 2021.
Metacrine to Present New Preclinical Data on MET642 in Inflammatory Bowel Disease at Digestive Disease Week 2021 Virtual Meeting
Preclinical data demonstrate synergistic effects between FXR agonist and JAK inhibitor, suggesting the potential for a change in the treatment paradigm for IBD Preclinical data demonstrate synergistic effects between FXR agonist and JAK inhibitor, suggesting the potential for a change in the treatment paradigm for IBD
Metacrine Achieves Enrollment Target for MET642 Phase 2a Trial Interim Analysis
SAN DIEGO, May 18, 2021 (GLOBE NEWSWIRE) -- Metacrine, Inc. (NASDAQ:MTCR), a clinical-stage biopharmaceutical company pioneering differentiated therapies for patients with liver and gastrointestinal diseases, today announced it has enrolled the first 60 patients in its MET642 Phase 2a trial. The Company remains on track to report interim results in the fourth quarter of 2021 after these patients have completed 16 weeks of treatment.
Metacrine to Present at 2021 RBC Global Healthcare Conference
SAN DIEGO, May 11, 2021 (GLOBE NEWSWIRE) -- Metacrine, Inc. (NASDAQ:MTCR), a clinical-stage biopharmaceutical company pioneering differentiated therapies for patients with liver and gastrointestinal diseases, today announced that Preston Klassen, M.D., MHS, president and chief executive officer, will present virtually at the 2021 RBC Global Healthcare Conference at 5:25 p.m. ET on Tuesday, May 18, 2021.
Metacrine Appoints Dr. Julia C. Owens to Its Board of Directors
SAN DIEGO, April 05, 2021 (GLOBE NEWSWIRE) -- Metacrine, Inc. (NASDAQ:MTCR), a clinical-stage biopharmaceutical company pioneering differentiated therapies for patients with liver and gastrointestinal diseases, today announced the appointment of Julia C. Owens, Ph.D. to the Company's board of directors, effective April 1, 2021. Dr. Owens will serve as a member of the Compensation Committee.
Metacrine to Present Final Results from Phase 1 Trial of MET642, an Optimized FXR Agonist, at the 2021 NASH-TAG Conference
Sustained pharmacodynamic effects with once-daily oral dosing, without increases in LDL cholesterol or pruritus at any dose level in healthy volunteers Sustained pharmacodynamic effects with once-daily oral dosing, without increases in LDL cholesterol or pruritus at any dose level in healthy volunteers
Metacrine Announces Date of Fourth Quarter and Full Year 2020 Financial Results Conference Call
SAN DIEGO, March 11, 2021 (GLOBE NEWSWIRE) -- Metacrine, Inc. (Nasdaq: MTCR), a clinical-stage biopharmaceutical company focused on discovering and developing differentiated therapies for patients with liver and gastrointestinal diseases, today announced that management will host a conference call and webcast to discuss its fourth quarter and full year 2020 financial results and other business highlights on Thursday, March 18, 2021 at 8:30 a.m. ET.
Metacrine to Present at H.C. Wainwright 2021 Global Life Sciences Conference
SAN DIEGO, March 02, 2021 (GLOBE NEWSWIRE) -- Metacrine, Inc. (Nasdaq: MTCR), a clinical-stage biopharmaceutical company focused on discovering and developing differentiated therapies for patients with liver and gastrointestinal diseases, today announced that Preston Klassen, M.D., MHS, president and chief executive officer of Metacrine, will present at the H.C. Wainwright 2021 Global Life Sciences Conference, being held March 9-10, 2021.
Metacrine to Present at SVB Leerink 10th Annual Global Healthcare Conference
SAN DIEGO, Feb. 19, 2021 (GLOBE NEWSWIRE) -- Metacrine, Inc. (Nasdaq: MTCR), a clinical-stage biopharmaceutical company focused on discovering and developing differentiated therapies for patients with liver and gastrointestinal diseases, today announced that Preston Klassen, M.D., MHS, president and chief executive officer of Metacrine, will present at the SVB Leerink 10th Annual Global Healthcare Conference on Friday, February 26, 2021 at 4:20 p.m. ET.
3 Net-Net Working Capital Stocks
There are some investors who purchase stocks that are trading below their liquidation value because they believe they can make impressive gains out of their investments after the market has reassessed the share prices near or above the liquidation value. Should the company fail, these shareholders would, in theory, still be able to make money due to a difference between the liquidation value and purchasing price.
Metacrine Announces Publication of MET409 NASH Proof-of-Concept Study Results in the Journal of Hepatology
Publication highlights the first clinical evidence that the risk-benefit profile of FXR agonists can be enhanced through structural optimization Publication highlights the first clinical evidence that the risk-benefit profile of FXR agonists can be enhanced through structural optimization
Metacrine Announces FDA Fast Track Designation for MET642 as a Treatment of NASH
SAN DIEGO, Jan. 19, 2021 (GLOBE NEWSWIRE) -- Metacrine, Inc. (Nasdaq: MTCR), a clinical-stage biopharmaceutical company focused on discovering and developing differentiated therapies for patients with liver and gastrointestinal diseases, today announced that the U.S. Food & Drug Administration (FDA) has granted Fast Track designation to MET642, the company's second farnesoid X receptor (FXR) agonist, for the treatment of non-alcoholic steatohepatitis (NASH).
Similar Companies
Related Metrics
Explore detailed financial metrics and analysis for MTCR.